The University of Southampton
University of Southampton Institutional Repository

Mechanisms of killing by anti-CD20 monoclonal antibodies

Glennie, Martin J., French, Ruth R., Cragg, Mark S. and Taylor, Ronald P. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies Molecular Immunology, 44, (16), pp. 3823-3837. (doi:10.1016/j.molimm.2007.06.151).

Record type: Article


CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as rituximab and ofatumumab, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment. This allows mAb to persist on the cell surface for extended periods and deliver sustained immunological attack from complement and FcR-expressing innate effectors, particularly macrophages. CD20 can also generate transmembrane signals when engaged by certain mAb which, although unproven, might provide an important element of the therapeutic success of anti-CD20 mAb. These favourable characteristics have led to anti-CD20 mAb being developed and exploited for use in immunotherapy, where they have proven remarkably efficacious in both the treatment of malignant disease and autoimmune disorders by deleting malignant or normal B cells, respectively. In this review, we discuss how these mAb have driven research in the immunotherapy field over the last decade, detail their likely modes of action and their limitations in terms of effector exhaustion, and explore ways in which they might be enhanced and further exploited in the future.

Full text not available from this repository.

More information

Published date: September 2007
Additional Information: XIth European meeting on Complement in Human Disease
Keywords: chronic lymphocytic-leukemia, the shaving reaction, cells, pcd, innate, therapeutic activity, cdc, non-hodgkins-lymphoma, disease, lived plasma-cells, cell, fc-gamma receptors, monoclonal antibody, monoclonal-antibodies, immunotherapy, b cell, adcc, cd20, complement-mediated lysis, rituximab, systemic-lupus-erythematosus, mechanism, human b-cells, rituximab in-vitro, effector exhaustion, dependent cellular cytotoxicity


Local EPrints ID: 62755
ISSN: 0161-5890
PURE UUID: 65001838-be2a-4f1c-9dd0-c8d22599c6b2
ORCID for Mark S. Cragg: ORCID iD

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 17 Jul 2017 14:20

Export record



Author: Ruth R. French
Author: Mark S. Cragg ORCID iD
Author: Ronald P. Taylor

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.